Check out this morning’s top movers from around Wall Street, compiled by The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HIGHER –
- Tempest Therapeutics (TPST) up 28% after announcing an agreement with Roche (RHHBY) to advance the evaluation of amezalpat in combination with atezolizumab and bevacizumab into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma
- GXO Logistics (GXO) up 10% after Bloomberg reported GXO Logistics is working with financial advisers to explore a potential sale
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
LOWER –
- 10x Genomics (TXG) down 28% after reporting preliminary Q3 results that CEO Serge Saxonov said “fell short of our expectations”
- Pfizer (PFE) down 1% after CEO Ian Read and former Pfizer CFO Frank D’Amelio decided not to be involved in the efforts of Starboard Value to push for change at the company
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Therapeutics announces agreement with Roche for amezalpat combo therapy
- Tempest Therapeutics extends limited duration of stockholder rights plan
- Tempest Therapeutics appoints Sheldon Mullins as VP, regulatory affairs
- Tempest Therapeutics appoints Troy Wagner as VP, quality assurance
- Tempest announces feedback form End-of-Phase 2 meeting with FDA for TPST-1120